<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Gynecology</journal-id><journal-title-group><journal-title xml:lang="en">Gynecology</journal-title><trans-title-group xml:lang="ru"><trans-title>Гинекология</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2079-5696</issn><issn publication-format="electronic">2079-5831</issn><publisher><publisher-name xml:lang="en">Consilium Medicum</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">76151</article-id><article-id pub-id-type="doi">10.26442/20795696.2021.3.200878</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLE</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Possibilities of using platelet-rich autoplasm in the complex treatment of patients with intrauterine synechiae</article-title><trans-title-group xml:lang="ru"><trans-title>Возможности применения аутоплазмы, обогащенной тромбоцитами, в комплексном лечении больных с внутриматочными синехиями</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6795-1033</contrib-id><name-alternatives><name xml:lang="en"><surname>Martynov</surname><given-names>Sergey A.</given-names></name><name xml:lang="ru"><surname>Мартынов</surname><given-names>Сергей Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, вед. научный сотрудник гинекологического отд-ния</p></bio><email>s_martynov@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3253-4512</contrib-id><name-alternatives><name xml:lang="en"><surname>Adamyan</surname><given-names>Leyla V.</given-names></name><name xml:lang="ru"><surname>Адамян</surname><given-names>Лейла Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof., Acad. RAS</p></bio><bio xml:lang="ru"><p>академик РАН, доктор медицинских наук, профессор, зам. директор по научный работе, руководитель гинекологического отд-ния</p></bio><email>l_adamyan@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3217-1141</contrib-id><name-alternatives><name xml:lang="en"><surname>Arakelyan</surname><given-names>Alek S.</given-names></name><name xml:lang="ru"><surname>Аракелян</surname><given-names>Алек Сейранович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, научный сотрудник гинекологического отд-ния</p></bio><email>A_arakelyan@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6883-4456</contrib-id><name-alternatives><name xml:lang="en"><surname>Fyodorova</surname><given-names>Tatyana A.</given-names></name><name xml:lang="ru"><surname>Федорова</surname><given-names>Татьяна Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>D. Sci. (Med.), Prof.</p></bio><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующий отделения трансфузиологии и экстракорпоральной гемокоррекции</p></bio><email>t_fyodorova1@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7472-4683</contrib-id><name-alternatives><name xml:lang="en"><surname>Bystrykh</surname><given-names>Oksana A.</given-names></name><name xml:lang="ru"><surname>Быстрых</surname><given-names>Оксана Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.)</p></bio><bio xml:lang="ru"><p>кандидат медицинских наук, заведующий отд-нием трансфузиологической иммунологии и заготовки компонентов крови</p></bio><email>o_bystrykh@oparina4.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology</institution></aff><aff><institution xml:lang="ru">ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Минздрава России</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2021-08-13" publication-format="electronic"><day>13</day><month>08</month><year>2021</year></pub-date><volume>23</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>250</fpage><lpage>254</lpage><history><date date-type="received" iso-8601-date="2021-07-17"><day>17</day><month>07</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-07-17"><day>17</day><month>07</month><year>2021</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2021, Consilium Medicum</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2021, ООО "Консилиум Медикум"</copyright-statement><copyright-year>2021</copyright-year><copyright-holder xml:lang="en">Consilium Medicum</copyright-holder><copyright-holder xml:lang="ru">ООО "Консилиум Медикум"</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc-sa/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://gynecology.orscience.ru/2079-5831/article/view/76151">https://gynecology.orscience.ru/2079-5831/article/view/76151</self-uri><abstract xml:lang="en"><p><bold>Aim. </bold>To increase the effectiveness of complex treatment of women with intrauterine synechiae (IS) through intrauterine administration of platelet-rich plasma (PRP).</p> <p><bold>Materials and methods. </bold>The authors studied the complex treatment results of 60 women with second and third degree intrauterine synechiae: 20 patients in the active treatment group, after hysteroscopic destruction of intrauterine synechiae, underwent intraoperative subendometrial administration of PRP followed by irrigating the uterine cavity with PRP on the 2nd and 3rd days after the operation, along with complex postoperative treatment (antibacteria and cyclic hormone therapy, physiotherapy); 40 patients in the comparison group underwent only complex postoperative treatment without PRP administration. The authors conducted comparative assessments of menstrual function, endometrial thickness and uterine cavity during check-up hysteroscopy procedure.</p> <p><bold>Results. </bold>Two months after the treatment, a statistically more significant increase in the thickness of endometrial tissue was found with the use of PRP compared with patients treated without PRP (<italic>p</italic>=0.03 and 0.04). Statistically more significant changes in the state of the uterine cavity were revealed when using PRP in the group of patients with the second-degree process severity (<italic>p</italic>=0.00005), while in patients with the third-degree process severity there were no statistically significant differences identified depending on the method of treatment used. The authors confirm high safety and reliability of the method as well as no adverse reactions to parenteral and intracavitary administration of autologous PRP.</p> <p><bold>Conclusion. </bold>The study confirmed applicability and prospects of using PRP as a stage in complex treatment of IS patients.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Цель. </bold>Повысить эффективность комплексного лечения женщин с внутриматочными синехиями (ВС) посредством внутриматочного введения обогащенной тромбоцитами плазмы (ОТП).</p> <p><bold>Материалы и методы.</bold> Проведен анализ результатов комплексного лечения 60 женщин с ВС II–III степени: 20 пациенткам основной группы после гистероскопического разрушения ВС интраоперационно проводилось субэндометриальное введение ОТП с последующим орошением полости матки ОТП на 2 и 3-и сутки после операции наряду с комплексным послеоперационным лечением (антибактериальная, циклическая гормональная терапия, физиотерапия); 40 пациенткам группы сравнения проводилось только комплексное послеоперационное лечение без введения ОТП. Проведена сравнительная оценка менструальной функции, толщины эндометрия и состояния полости матки при контрольной гистероскопии.</p> <p><bold>Результаты. </bold>Через 2 мес после проведенного лечения установлено статистически более значимое увеличение толщины эндометрия при использовании ОТП по сравнению с больными, получавшими лечение без ОТП (<italic>р</italic>=0,03 и 0,04). Достоверно более значимые изменения состояния полости матки выявлены при использовании ОТП в группе больных со II степенью тяжести процесса (<italic>р</italic>=0,00005), тогда как у больных с III степенью тяжести процесса (синдромом Ашермана) статистически значимых различий в зависимости от применяемого метода лечения выявлено не было. Подтверждены высокая безопасность метода и отсутствие побочных реакций на парентеральное и внутриполостное введение аутологичной ОТП.</p> <p><bold>Заключение. </bold>Исследование подтвердило приемлемость и перспективность использования ОТП в качестве этапа комплексного лечения больных с ВС.</p></trans-abstract><kwd-group xml:lang="en"><kwd>intrauterine synechiae</kwd><kwd>Asherman syndrome</kwd><kwd>platelet-rich plasma</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>внутриматочные синехии</kwd><kwd>синдром Ашермана</kwd><kwd>обогащенная тромбоцитами плазма</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Хириева П.М., Адамян Л.В., Мартынов С.А. Современные методы профилактики и лечения внутриматочных синехий (обзор литературы). Гинекология. 2016;18(5):32-6 [Khirieva PM, Adamyan LV, Martynov SA. Modern methods of prevention and treatment of intrauterine adhesions (literature review). Gynecology. 2016;18(5):32-6 (in Russian)].</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Хириева П.М., Мартынов С.А., Быстрицкий А.А., Адамян Л.В. Генетические факторы риска формирования внутриматочных синехий (обзор литературы). Проблемы репродукции. 2017;23(1):39-44 [Khirieva PM, Martynov SA, Bystritskii AA, Adamyan LV. Intrauterine adhesions: genetic risk factors (a review). Russian Journal of Human Reproduction. 2017;23(1):39-44 (in Russian)]. DOI:10.17116/repro201723143-47</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hanstede MMF, van der Meij E, Goedemans L, Emanuel MH. Results of centralized Asherman surgery. Fertil Steril. 2015;104(6):1561-8.e1. DOI:10.1016/j.fertnstert.2015.08.039</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>AAGL Advancing Minimally Invasive Gynecology Worldwide. AAGL practice report: practice guidelines for management of intrauterine synechiae. J Minim Invasive Gynecol. 2010;17(1):1-7. DOI:10.1016/j.jmig.2009.10.009</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Dreisler E, Kjer JJ. Asherman’s syndrome: current perspectives on diagnosis and management. Int J Womens Health. 2019;11:191-8. DOI:10.2147/IJWH.S165474</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Ахмеров Р.Р. Регенеративная медицина на основе аутологичной плазмы. Технология PlasmoliftingTM. М.: Литтерра, 2014 [Akhmerov RR. Regenerative medicine based on autologous plasma. Technology PlasmoliftingTM. Moscow: Litterra, 2014 (in Russian)].</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>da Silva RT, Heidrich F. Therapy with Use of Platelet-Rich Plasma in Orthopedics and Sports Traumatology: Literature Review, Evidence and Personal Experience. Springer Berlin Heidelberg. 2014;р.53-70.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Dragoo JL, Wasterlain AS, Braun HJ, Nead KT. Platelet-rich plasma as a treatment for patellar tendinopathy: a double-blind, randomized controlled trial. Am J Sports Med. 2014;42(3):610-8. DOI:10.1177/0363546513518416</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Picard F, Hersant B, Bosc R, Meningaud JP. The growing evidence for the use of platelet-rich plasma on diabetic chronic wounds: A review and a proposal for a new standard care. Wound Repair Regen. 2015;23(5):638-43. DOI:10.1111/wrr.12317</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Обидняк Д.М., Гзгзян А.М., Ниаури Д.А., Чхаидзе И.З. Перспективы применения аутологичной обогащенной тромбоцитами плазмы крови у пациенток с повторными неэффективными попытками имплантации. Проблемы репродукции. 2017;23(5):84-8 [Obidniak DM, Gzgzyan AM, Niauri DA, Chkhaidze IZ. Prospects for the use of autologous platelet-rich plasma in patients with recurrent implantation failure. Russian Journal of Human Reproduction. 2017;23(5):84-8 (in Russian)]. DOI:10.17116/repro201723584-88</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Chang Y, Li J, Chen Y, et al. Autologous platelet-rich plasma promotes endometrial growth and improves pregnancy outcome during in vitro fertilization. Int J Clin Exp Med. 2015;8(1):1286-90.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Farimani M, Bahmanzadeh M, Poorolajal J. A New Approach Using Autologous Platelet-Rich Plasma (PRP) to Treat Infertility and To Improve Population Replacement Rate. J Res Health Sci. 2016;16(3):172-3.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Kim H, Shin JE, Koo HS, et al. Effect of Autologous Platelet-Rich Plasma Treatment on Refractory Thin Endometrium During the Frozen Embryo Transfer Cycle: A Pilot Study. Front Endocrinol (Lausanne). 2019;10:61. DOI:10.3389/fendo.2019.00061</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Nazari L, Salehpour S, Hoseini S, et al. Effects of autologous platelet-rich plasma on implantation and pregnancy in repeated implantation failure: A pilot study. Int J Reprod Biomed. 2016;14(10):625-8.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Tehranian A, Esfehani-Mehr B, Pirjani R, et al. Application of Autologous Platelet-Rich Plasma (PRP) on Wound Healing After Caesarean Section in High-Risk Patients. Iran Red Crescent Med J. 2016;18(7):e34449. DOI:10.5812/ircmj.34449</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Мартынов С.А., Адамян Л.В., Федорова Т.А., и др. Способ лечения внутриматочных синехий. Пат. 2741621 Российская Федерация, RU 2741621 C1. Заявитель и патентообладатель ФГБУ «Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова» Министерства здравоохранения РФ. №2020131585; заявл. 25.09.2020; опубл. 28.01.2021, Бюл. №4.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Хириева П.М., Мартынов С.А., Ежова Л.С., Адамян Л.В. Клинико-морфологические особенности эндометрия при внутриматочных синехиях: оценка экспрессии эстрогеновых и прогестероновых рецепторов. Акушерство и гинекология. 2018;9:48-54 [Khirieva PM, Martynov SA, Ezhova LS, Adamyan LV. Clinical and morphological characteristics of the endometrium in intrauterine synechiae: evaluation of the expression of estrogen and progesterone receptors. Akusherstvo i Ginekologiya. 2018;9:48-54 (in Russian)].DOI:10.18565/aig.2018.9.48-54</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Schenker JG. Etiology of and therapeutic approach to synechia uteri. Eur J Obstet Gynecol Reprod Biol. 1996;65(1):109-13. DOI:10.1016/0028-2243(95)02315-J</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Fedele L, Bianchi S, Frontino G. Septums and synechiae: approaches to surgical correction. Clin Obstet Gynecol. 2006;49(4):767-88. DOI:10.1097/01.grf.0000211948.36465.a6</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Johary J, Xue M, Zhu X, et al. Efficacy of estrogen therapy in patients with intrauterine adhesions: systematic review. J Minim Invasive Gynecol. 2014;21(1):44-54. DOI:10.1016/j.jmig.2013.07.018</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zinger M, Liu JH, Thomas MA. Successful use of vaginal sildenafil citrate in two infertility patients with Asherman’s syndrome. J Womens Health (Larchmt). 2006;15(4):442-4. DOI:10.1089/jwh.2006.15.442</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Стругацкий В.М., Маланова Т.Б., Арсланян К.Н. Физиотерапия в практике акушера-гинеколога: Клинические аспекты и рецептура. 2-е изд., испр. и доп. М.: МЕДпресс-информ, 2008 [Strugatskii VM, Malanova TB, Arslanian KN. Physiotherapy in the practice of an obstetrician-gynecologist: Clinical aspects and formulation. 2nd ed., rev. and exp. Moscow: MEDpress-inform, 2008 (in Russian)].</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Lin X, Wei M, Li TC, et al. A comparison of intrauterine balloon, intrauterine contraceptive device and hyaluronic acid gel in the prevention of adhesion reformation following hysteroscopic surgery for Asherman syndrome: a cohort study. Eur J Obstet Gynecol Reprod Biol. 2013;170(2):512-6. DOI:10.1016/j.ejogrb.2013.07.018</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Tsapanos VS, Stathopoulou LP, Papathanassopoulou VS, Tzingounis VA. The role of Seprafilm bioresorbable membrane in the prevention and therapy of endometrial synechiae. J Biomed Mater Res. 2002;63(1):10-4. DOI:10.1002/jbm.10040</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Acunzo G, Guida M, Pellicano M, et al. Effectiveness of auto-cross-linked hyaluronic acid gel in the prevention of intrauterine adhesions after hysteroscopic adhesiolysis: a prospective, randomized, controlled study. Hum Reprod. 2003;18(9):1918-21. DOI:10.1093/humrep/deg368</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Amer MI, Abd-El-Maeboud KHI, Abdelfatah I, et al. Human amnion as a temporary biologic barrier after hysteroscopic lysis of severe intrauterine adhesions: pilot study. J Minim Invasive Gynecol. 2010;17(5):605-11. DOI:10.1016/j.jmig.2010.03.019</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Chen X, Sun J, Li X, et al. Antifibrotic Effects of Decellularized and Lyophilized Human Amniotic Membrane Transplant on the Formation of Intrauterine Adhesion. Exp Clin Transplant. 2019;17(2):236-42.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Santamaria X, Cabanillas S, Cervelló I, et al. Autologous cell therapy with CD133+ bone marrow-derived stem cells for refractory Asherman’s syndrome and endometrial atrophy: a pilot cohort study. Hum Reprod. 2016;31(5):1087-96. DOI:10.1093/humrep/dew042</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Nagori CB, Panchal SY, Patel H. Endometrial regeneration using autologous adult stem cells followed by conception by in vitro fertilization in a patient of severe Asherman’s syndrome. J Hum Reprod Sci. 2011;4(1):43-8. DOI:10.4103/0974-1208.82360</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Lu H, Hu Y, Cui Z, Jia H. Human menstrual blood: a renewable and sustainable source of stem cells for regenerative medicine. Stem Cell Res Ther. 2018;9(1):325. DOI:10.1186/s13287-018-1067-y</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Zhang S, Li P, Yuan Z, Tan J. Platelet-rich plasma improves therapeutic effects of menstrual blood-derived stromal cells in rat model of intrauterine adhesion. Stem Cell Res Ther. 2019;10(1):61. DOI:10.1186/s13287-019-1155-7</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Oz M, Cetinkaya N, Bas S, et al. A randomized controlled experimental study of the efficacy of platelet-rich plasma and hyaluronic acid for the prevention of adhesion formation in a rat uterine horn model. Arch Gynecol Obstet. 2016;294(3):533-40. DOI:10.1007/s00404-016-4079-9</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Aghajanova L, Cedars MI, Huddleston HG. Platelet-rich plasma in the management of Asherman syndrome: case report. J Assist Reprod Genet. 2018;35(5):771-5. DOI:10.1007/s10815-018-1135-3</mixed-citation></ref></ref-list></back></article>
